Skip to main
  1. Stocks
  2. Compass Therapeutics
  3. Forecast
CMPX

Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics (CMPX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Therapeutics is supported by a differentiated bispecific antibody platform with multiple shots on goal, led by tovecimig’s positive COMPANION-002 readout showing 18% ORR versus 5.3% and median PFS of 4.7 months versus 2.6 months, alongside no new safety signals. The outlook remains constructive because the company has $179.9MM in cash to fund development, is advancing CTX-8371, CTX-10726, and CTX-471, and has key data expected in 4Q26, reducing near-term financing pressure while preserving pipeline optionality. Although the FDA requested an additional survival trial in 2L+ BTC, the company’s continued dialogue is viewed as the most prudent path in a setting of significant unmet need and a large potential market opportunity.

Bears say

Compass Therapeutics is facing a fundamentally difficult regulatory path because the FDA has recommended an additional survival-benefit trial before a tovecimig BLA, while the company has no confirmatory study enrolling and cannot yet resolve the agency’s concerns through meetings or further clarification. Although COMPANION-002 showed meaningful activity with ORR of 18.0% versus 5.3% and mPFS of 4.7 versus 2.6 months, overall survival was not statistically significant and the crossover-adjusted OS signal remains weak, leaving the approval case dependent on an argument regulators have already questioned. Financially, the company reported a Q3 net loss of $27.2 million, had $163 million in cash, and expects runway into 2028, but the valuation remains pressured by regulatory uncertainty and the risk that pipeline progress does not translate into revenue.

Compass Therapeutics (CMPX) has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Compass Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Compass Therapeutics (CMPX) Analyst Forecast & Price Prediction

Get the latest Compass Therapeutics (CMPX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Compass Therapeutics (CMPX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Compass Therapeutics (CMPX) Forecast

Analysts have given Compass Therapeutics (CMPX) a Buy based on their latest research and market trends.

According to 8 analysts, Compass Therapeutics (CMPX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.99, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.99, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Compass Therapeutics (CMPX)


Compass Therapeutics (CMPX) Analyst Forecast & Price Prediction

Get the latest Compass Therapeutics (CMPX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Compass Therapeutics (CMPX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CMPX stock data and trends